ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Idenix Pharmaceuticals, Inc. 

Corporate Headquarters
60 Hampshire Street
Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-995-9800 Fax: 617-995-9801


SEARCH JOBS
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. Idenix is advancing a robust product pipeline in HCV treatment with programs in four different HCV drug classes. The company’s clinical candidates include IDX184, a liver-targeted nucleotide polymerase inhibitor, IDX320, a protease inhibitor and IDX375, a non-nucleoside polymerase inhibitor. Idenix also has a preclinical NS5A inhibitor program. Idenix believes that the future of HCV treatment will include novel combinations of direct-acting antivirals (DAAs) which could eliminate the need for interferon and/or ribavirin. The company’s goal is to develop low dose, once- or twice-daily agents with broad genotypic activity, a low potential for drug-drug interaction and that are designed for use in multiple combination regimens. With programs that span the major HCV drug classes, Idenix is well positioned to build a combination drug development strategy, both internally and with partners, to advance the future HCV paradigm.

 Key Statistics


Email:
Ownership: Public

Web Site: Idenix Pharmaceuticals, Inc.
Employees: 200 + worldwide
Symbol: IDIX
 









 Company News
Merck & Co., Inc. (MRK) Completes Tender Offer To Acquire Idenix Pharmaceuticals, Inc. (IDIX) 8/5/2014 10:19:26 AM
Idenix Pharmaceuticals, Inc. (IDIX) Reports Second Quarter And Six Month 2014 Financial Results 8/1/2014 10:19:37 AM
Merck & Co., Inc. (MRK) Begins Tender Offer To Acquire Idenix Pharmaceuticals, Inc. (IDIX) 6/20/2014 10:31:18 AM
Merck & Co., Inc. (MRK) Open To More Biotech Deals After Idenix Pharmaceuticals, Inc. (IDIX): Research Chief 6/13/2014 6:27:25 AM
AbbVie (ABBV) And Johnson & Johnson (JNJ) Were In A Bidding War For Idenix Pharmaceuticals, Inc. (IDIX), Will Achillion Pharmaceuticals, Inc. (ACHN) Be The Next Target? 6/12/2014 5:38:38 AM
Merck & Co., Inc. (MRK) Snags Cambridge's Idenix Pharmaceuticals, Inc. (IDIX) For $3.85 Billion 6/9/2014 6:29:10 AM
Idenix Pharmaceuticals, Inc. (IDIX) Reports First Quarter 2014 Financial Results And HCV Pipeline Review 5/1/2014 4:42:32 PM
Idenix Pharmaceuticals, Inc. (IDIX) To Present At Three Upcoming Healthcare Conferences 4/30/2014 9:45:48 AM
Idenix Pharmaceuticals, Inc. (IDIX)'s "Good" News Shows Hep C Drug Market Increasingly Murky For Investors 4/9/2014 6:05:01 AM
Idenix Pharmaceuticals, Inc. (IDIX) Announces Promising Clinical Data And Continued Progress In Nucleotide Prodrug Development Programs For The Treatment Of Hepatitis C 4/7/2014 9:29:00 AM
12345678910...